The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICLE 2022 | Generating neoantigen-specific CAR T-cell therapies for multiple myeloma
Angela Krackhard, MD, PhD, Technical University of Munich, Munich, Germany, gives an overview of targeting neoantigens in patients with multiple myeloma. Personalized treatments for multiple myeloma are currently limited due to manufacturing constraints and patients requiring treatment in a short amount of time. With the approval of idecabtagene vicleucel and ciltacabtagene autoleucel, chimeric antigen receptor (CAR) T-cell therapies represent a promising treatment strategy for multiple myeloma. However, there are remaining issues that need to be addressed, including tumor heterogeneity, antigen escape and the tumor microenvironment. Prof. Krackhard subsequently describes the specificity of neoantigens and how they can tackle the aforementioned challenges. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.
